Ito, Seiji
Kanda, Mitsuro
Mochizuki, Yoshinari
Teramoto, Hitoshi
Ishigure, Kiyoshi
Murai, Toshifumi
Asada, Takahiro
Ishiyama, Akiharu
Matsushita, Hidenobu
Tanaka, Chie
Kobayashi, Daisuke
Fujiwara, Michitaka
Murotani, Kenta
Kodera, Yasuhiro
Article History
Accepted: 7 May 2021
First Online: 3 June 2021
Declarations
:
: Dr. Ito reports grants from MSD, grants from Ono Pharma, personal fees from Taiho Pharma, personal fees from Astra Zeneca, outside the submitted work. Dr. Kodera reports grants from Taiho Pharma, grants from Chugai Pharma, grants from Takeda, grants from MSD, grants from Nihon Kayaku, grants from Yakult, grants from Lilly Japan, grants from Ono Pharma, grants from Kaken Pharma, grants from Covidien, grants from EA Pharma, grants from Novartis, grants from KCI, grants from Maruho, grants from Daiichi Sankyo, grants from Otsuka, grants from Tsumura, grants from Sawai, personal fees from Taiho Pharma, personal fees from Chugai Pharma, personal fees from Lilly Japan, personal fees from Johnson & Johnson, personal fees from Takeda, personal fees from Yakult, personal fees from Otsuka, personal fees from Ono Pharma, personal fees from Covidien, personal fees from MSD, grants from Bristol, grants from Sanofi, outside the submitted work. Other authors have nothing to disclose.
: Written, informed consent for use of clinical data was granted when required by the Institutional Review Board at each participating institute. In some institutions, opt-out recruitment was employed according to the policy of the Japanese government because this clinical research was conducted using only retrospective clinical data without intervention. The purpose, design, and objectives of the study were posted on the homepage of the Nagoya University Graduate School of Medicine to provide an opportunity for patients to decline to contribute to our study.
: This study conformed fully to the ethical guidelines of the World Medical Association Declaration of HelsinkiāEthical Principles for Medical Research Involving Human Subjects.